People who take Ozempic, Wegovy, Mounjaro or Zepbound for diabetes or weight loss are about to see a new entry required in the warnings section of the drug’s prescribing information: a rare condition that can cause sudden, painless vision loss in one eye. On Nov. 9, 2026, the Food and Drug Administration said it is requiring that addition across the entire class of GLP-1 drugs.
The agency’s wording is cautious. It describes a “potential increased risk” of non-arteritic anterior ischemic optic neuropathy, or NAION, and says the absolute risk remains low. The requirement, though, applies to every application holder in the class.
FDA’s Nov. 9 safety communication
The agency’s Drug Safety Communication says FDA is requiring application holders for all GLP-1 receptor agonist medications to add NAION risk information to the Warnings and Precautions section of labeling. The page does not state a deadline for manufacturers to make the change.
It lists the affected products by trade name: Byetta (exenatide, whose application was withdrawn for reasons other than safety, leaving only generic exenatide on the market), Victoza, Trulicity, Saxenda, Xultophy, Soliqua, Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound and, approved in 2026, Foundayo. Tirzepatide, in Mounjaro and Zepbound, also acts on the GIP receptor, and FDA footnotes that distinction while still including it.
FDA describes NAION as “a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss.”
The trial and cohort numbers behind it
FDA’s conclusion rests on three kinds of evidence, and the numbers are modest. A meta-analysis of 126 randomized controlled trials covering 134,253 patients found NAION in 6.4 cases per 100,000 person-years among GLP-1 users, against 3.8 for comparators. That works out to 15 probable events, 10 in the GLP-1 groups and 5 in placebo.
A cohort study in the agency’s Sentinel system of adults with type 2 diabetes was less conclusive. Compared with SGLT-2 inhibitors, the hazard ratio was 1.19 with a 95 percent confidence interval of 0.91 to 1.54, which is not statistically significant. Compared with DPP-4 inhibitors, it was 1.43, with an interval of 1.02 to 2.01. FDA also said observational studies it judged rigorous generally found higher risk against those two comparison groups.
Animal data offered no help: FDA reported that no mechanism linking GLP-1 drugs to NAION was identified. Background incidence in the general population, it said, runs 2.3 to 10.2 per 100,000 adults over 50. The agency’s own summary line is that it “concluded that there is a potential increased risk of rare NAION events in patients taking GLP-1 RAs.”
Guidance for patients and clinicians
FDA tells patients to contact a health care professional right away for sudden painless vision loss in one eye, blind spots or tunnel vision, color distortion, or blurry or hazy central vision. Anyone who has had NAION is advised to discuss with a clinician whether to continue the drug. Known risk factors named by the agency include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease, and a person who has had NAION in one eye has a higher risk in the other.
For clinicians, the page says to instruct patients to report such symptoms immediately, to refer suspected cases promptly to an ophthalmologist, and to consider discontinuing the GLP-1 drug in patients who develop NAION unless the benefits clearly outweigh the risk. Adverse events can be reported through MedWatch online or at 1-800-332-1088.
The change also cuts against the direction of FDA’s most recent GLP-1 labeling action. In a separate communication dated Jan. 13, 2026, the agency asked manufacturers to remove a psychiatric-risk warning from the labels of Saxenda, Wegovy and Zepbound after a review of 91 placebo-controlled trials with 107,910 patients found no increased risk. The two decisions show the agency adding and subtracting warnings on the same drug class within ten months, each time based on pooled trial data and a claims cohort study.
Drugmaker responses and the European precedent
Novo Nordisk, which makes Ozempic and Wegovy, responded through spokesperson Liz Skrbkova that the data “do not establish a cause-and-effect relationship” and that the company remains confident in the benefit-risk profile of its GLP-1 medicines, Review of Optometry reported on Nov. 10. An unnamed Eli Lilly spokesperson said the FDA communication “does not reference any findings specific to Lilly medicines” and that the company is evaluating the update.
The U.S. action follows a European one. In June 2025, the European Medicines Agency’s safety committee concluded that NAION is a “very rare side effect” of semaglutide, meaning it may affect up to 1 in 10,000 people taking it, and said treatment should stop if NAION is confirmed. The signal had been raised by a 2024 study in JAMA Ophthalmology, per Review of Optometry.
The European finding covered semaglutide alone. The FDA requirement is broader, reaching every drug in the class, and Ophthalmology Times also lists orforglipron among them. What the FDA has not published is the date by which the new language must appear on each label, and so the timing of the change at the pharmacy counter is still open.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Arizona’s governor declared a statewide emergency after Flagstaff logged its wettest Nov. 1 on record
- Zero Motorcycles unveiled an electric motorcycle targeted at under $8K and a street-legal dirt bike at EICMA
- New FCC rules on how people can stop robocalls and texts take effect Nov. 25
- Neanderthals in Spain carved a wooden object that matches nothing archaeologists have ever found